Paul R, Sathe P, Kumar RS, Prasad S, Aleem M, Sakhalvalkar P. Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock. World J Crit Care Med 2021; 10(1): 22-34 [PMID: 33505870 DOI: 10.5492/wjccm.v10.i1.22]
Corresponding Author of This Article
Rajib Paul, DNB, MD, Doctor, Professor, Department of Internal Medicine and Critical Care, Apollo Health City, Road Number 72, opp, Bharatiya Vidya Bhavan School, Jubilee Hills, Hyderabad 500033, India. rajib.paulcriticalcare@gmail.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Prospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Crit Care Med. Jan 9, 2021; 10(1): 22-34 Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock
Rajib Paul, Ma Aleem, Department of Internal Medicine and Critical Care, Apollo Health City, Hyderabad 500033, India
Prachee Sathe, Prashant Sakhalvalkar, Department of Critical Care Medicine, Ruby Hall Clinic, Pune 411001, India
Senthil Kumar, Department of Critical Care Medicine, Apollo Hospital, Chennai 600006, India
Shiva Prasad, Department of Anesthesiology and Critical Care, Narayana Institute of Cardiac Sciences, Bangaluru 560099, India
Author contributions: Paul R and Sathe P contributed to study design/planning, review of the study protocol, enrollment of study subjects, follow-up and data collection and review of manuscript; Kumar S and Prasad S were involved in study design/planning, review of the study protocol, enrollment of study subjects, follow-up and data collection, review of manuscript, data collection/entry, data analysis/statistics, data interpretation, preparation of manuscript, literature analysis/search and data management; Aleem M and Sakhalvalkar P participated in data collection/entry, data analysis/statistics, data interpretation, preparation of manuscript, literature analysis/search and data management.
Institutional review board statement: This study was reviewed and approved by an institutional ethics committee.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: There is no additional data available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rajib Paul, DNB, MD, Doctor, Professor, Department of Internal Medicine and Critical Care, Apollo Health City, Road Number 72, opp, Bharatiya Vidya Bhavan School, Jubilee Hills, Hyderabad 500033, India. rajib.paulcriticalcare@gmail.com
Received: June 2, 2020 Peer-review started: June 2, 2020 First decision: July 4, 2020 Revised: September 3, 2020 Accepted: November 28, 2020 Article in press: November 28, 2020 Published online: January 9, 2021 Processing time: 217 Days and 16.8 Hours
Core Tip
Core Tip: This prospective, real time, observational multicenter study was conducted in 45 patients with sepsis and septic shock. Post therapy, 26 patients survived and dose reduction in norepinephrine, epinephrine and vasopressin was 51.4%, 69.4% and 13.9%, respectively. Interleukin-6 level reduction was 52.3%, and platelet count improved significantly to 30.1%. Mean acute physiology and chronic health evaluation and sequential organ failure assessment scores were reduced significantly. Predicted mortality before CytoSorb® therapy was 56.5%, and mortality reduced to 48.8% after CytoSorb® therapy. The survival rate in patients given treatment in < 24 h of intensive care unit admission was 75% and 68% when given within 24-48 h of intensive care unit admission. CytoSorb® therapy was safe and well tolerated with no adverse events reported.
